Poor efficacy undermines Genentech metastatic breast cancer indication for Avastin
This article was originally published in Scrip
Executive Summary
Genentech's strategy of asking for a hearing at the US FDA on whether the agency should remove the metastatic breast cancer (MBC) indication for Avastin (bevacizumab), its VEGF-targeting drug, for appears not to have paid off. The six members of the agency's oncology drug advisory committee who were on the panel for the hearing on July 29 all voted to recommend that FDA Commissioner Margaret Hamburg drop the label language immediately.